UNMC

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Association of American Physicians, Faculty, American College, ASCO, Dean, MD Anderson Cancer Center, Vice, Clinical professor, Hematology, American Society of Clinical Oncology, Advisory board, University of Nebraska Medical Center, Department of Medicine – University of Pamplona, Clinical Oncology, Society, Internal medicine, UNMC, College, Membership of the Royal College of Physicians of Ireland, Royal college, Nebraska Medicine, Division, Richard, University, American College of Physicians, Mayo Clinic, Cancer, Patient, American Association for Cancer Research, Transplant, Book, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Nursing, Medical device, Physician

Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

Key Points: 
  • Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
  • Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
  • “We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune.
  • He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.

University of Nebraska Medical Center and ANANDA Scientific announce First Patient Enrolled in FDA-approved clinical trial for Post-Traumatic Stress Disorder (PTSD)

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, FDA, Health, Cannabis, Pharmaceutical, Neurology, Mental Health, Natural Resources, Research, Science, Clinical Trials, Systems neuroscience, University, Clinical trial, Advanced practice nurse, Nebraska Medicine, Doctor of Philosophy, FANA, Psychiatry, PTSD, UNMC, Cannabidiol, Liquid, MD, FAAN, Multimedia, Assistant, University of Nebraska Medical Center, Safety, Therapy, Post-traumatic stress disorder, Reynolds, Pharmaceutical industry, Nursing

The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. today announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology, for Post-Traumatic Stress Disorder (PTSD).

Key Points: 
  • The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. today announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology, for Post-Traumatic Stress Disorder (PTSD).
  • ( Clinical Trials.gov Identifier NCT05269459 )
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230314005182/en/
    Pictured above is principal investigator Matthew Rizzo, MD, FAAN, FANA, and Ananda Scientific CEO Sohail Zaidi.
  • “Enrolling the first patient in our second PTSD clinical trial is an important milestone for ANANDA’s clinical development program,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer.

Bone Health Technologies announces positive Topline Results from Groundbreaking Pivotal Trial of Non-pharmacological Treatment for Osteopenia

Retrieved on: 
Monday, December 5, 2022
Osteoporosis, College, BHT, Woman, SAN, Research, Partnership, University of Nebraska Medical Center, FDA, CT, Dean (education), Science, NASA, Kawasaki College of Allied Health Professions, Nebraska Medicine, Vibration, Federal law, Osteopenia, NIH, UNMC, Bone density, Risk, University, Patient, Medical imaging, Dietary supplement

SAN FRANCISCO, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Bone Health Technologies (BHT), a leading innovator of technologies for improving bone health, announces today topline results of its pivotal trial of the Osteoboost Vibration Belt.

Key Points: 
  • SAN FRANCISCO, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Bone Health Technologies (BHT), a leading innovator of technologies for improving bone health, announces today topline results of its pivotal trial of the Osteoboost Vibration Belt.
  • “There is a clear public health need and patient desire for a non-pharmacological intervention for bone strength.
  • These results demonstrate a huge step forward for the treatment of osteopenia and the potential prevention of osteoporosis.
  • Bone Health Technologies is poised to become the new standard of care in treating osteoporosis and osteopenia (the precursor to osteoporosis).

Innovate Conference Spotlights Nebraska’s Bioscience Ecosystem

Retrieved on: 
Thursday, October 20, 2022
Nebraska Medicine, Growth, Conference, Technology transfer, UNMC, Research, University of Nebraska Medical Center, Omaha–Council Bluffs metropolitan area, University, Economic development, Health, CEO, Greater Omaha Chamber of Commerce, Leadership, GLOBE, VIP, Omaha Public Power District, Uneme language, Public health, Car rental, Management

The Innovate Conference featured a keynote from Dr. Jim Linder, CEO of Nebraska Medicine and founder of Linseed Capital.

Key Points: 
  • The Innovate Conference featured a keynote from Dr. Jim Linder, CEO of Nebraska Medicine and founder of Linseed Capital.
  • The Innovate Nebraska conference was a great opportunity for us to connect the amazing breakthroughs being made in Nebraska with business leaders who can help bring those innovations to market and grow our local medtech ecosystem.
  • Innovate Nebraska led into the Bio Nebraska annual meeting, where Governor Pete Ricketts presented the Governors Bioscience Award.
  • Earlier this month, Governor Ricketts officially proclaimed the month of October as Bioscience Month in Nebraska.

Berenberg Continues U.S. Philanthropic Efforts at Annual Charity Golf Event in New York

Retrieved on: 
Thursday, October 6, 2022
Pancreatic cancer, Nebraska Medicine, Disease, UNMC, Research, University of Nebraska Medical Center, Partnership, History, University, NEW, Drug discovery, Player of the year award, PGA Tour, Name, Biomarker, Pharmaceutical industry, Bank, Berenberg family

NEW YORK, October 06, 2022  /PRNewswire-PRWeb/ -- Berenberg, the world's second oldest bank, utilized their presence in New York to host professional golfers and clients for the Berenberg Invitational to raise invaluable funds for charitable causes.

Key Points: 
  • NEW YORK, October 06, 2022 /PRNewswire-PRWeb/ -- Berenberg , the world's second oldest bank, utilized their presence in New York to host professional golfers and clients for the Berenberg Invitational to raise invaluable funds for charitable causes.
  • This year's Berenberg Invitational at GlenArbor Golf Club raised $750,000 for pancreatic cancer research at the University of Nebraska Medical Center and Nebraska Medicine, bringing Berenberg's combined donation over two tournaments to $1,450,000.
  • Our focus on charitable efforts will never waiver, and our Berenberg Invitational would not be possible without the generous contributions made by both our clients and an incredible field of participants."
  • Berenberg has held an annual charity golf event in New York featuring legends of the game for nearly a decade.

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Retrieved on: 
Wednesday, July 20, 2022
Erasmus MC, CFS, Congress, University, GLOBE, Lists of diseases, Inspectorate, Lead, Doctor of Philosophy, LAPC, NYSE, Research, Pancreatic cancer, AIM, CRO, Private Securities Litigation Reform Act, Intention, Cancer, Chronic fatigue syndrome, Immune system, COVID-19, Safety, Clinical trial, EAP, Disease, Nebraska Medicine, Company, MD, UNMC, University of Nebraska Medical Center, Patient, American, PSLRA, Medi-Cal Access Program, Overalls, Professor, Therapy, Survival, Hope, Progression-free survival, Program, FOLFIRINOX, Observation, Degenerative disease, Pharmaceutical industry, Rintatolimod

OCALA, Fla., July 20, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported follow-on data from its previously published single-center named patient program. For the study, patients with locally advanced pancreatic cancer or metastatic disease were treated following FOLFIRINOX (See: Cancers 2022).

Key Points: 
  • For the study, patients with locally advanced pancreatic cancer or metastatic disease were treated following FOLFIRINOX (See: Cancers 2022 ).
  • Multi-year survival rates for LAPC and metastatic pancreatic cancer patients are historically low, with 5-year survival typically less than 3%.
  • These additional data, indicating major improvements to survival at 24 months and beyond, point to the potential value of Ampligen as a therapy for pancreatic cancer patients.
  • The data bolster our confidence in the potential of Ampligen for the treatment of late-stage pancreatic cancer and represents a big step forward in Ampligens therapeutic development program.

Berenberg and Gary Player Continue Strong Partnership with the University of Nebraska Medical Center & Nebraska Medicine in the Battle Against Pancreatic Cancer

Retrieved on: 
Thursday, May 19, 2022
Cancer, University of Nebraska Medical Center, Education, Chancellor, Disease, Medicine, Investment banking, Fred, Patient, Golf, Health, NCI, Nebraska Medicine, Clinical trial, Survival rate, ATP Challenger Tour, Research, National Cancer Institute, BioNTech, Partnership, Center, UNMC, Man, University, Biomarker, IPO, Corporation, Pancreatic cancer, Drug discovery, Bank, Pharmaceutical industry, AbCellera

OMAHA, Neb., May 19, 2022 /PRNewswire-PRWeb/ -- Ahead of this year's Berenberg Invitational charity tournament, golf legend Gary Player visited the University of Nebraska Medical Center and the Fred & Pamela Buffett Cancer Center, the event's beneficiaries, this week to immerse himself in one of the top research and treatment facilities in the world for pancreatic cancer. This renewed partnership will provide additional funding for the Center from monies raised at the event this October.

Key Points: 
  • This renewed partnership will provide additional funding for the Center from monies raised at the event this October.
  • "I, along with Berenberg, the University of Nebraska Medical Center and Nebraska Medicine leaders, researchers, and clinicians at the Fred & Pamela Buffett Cancer Center, believe pancreatic cancer is a curable disease," said Player.
  • The UNMC partnership with Berenberg has already resulted in research innovation funding from the Berenberg Invitational, a charity golf event that raised $700,000 in 2021.
  • The University of Nebraska Medical Center and Nebraska Medicine partner to provide exceptional patient care combined with innovative research and education.

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD)

Retrieved on: 
Tuesday, May 17, 2022
Men, Research, Pharmaceutical, Consumer, University, Education, Clinical Trials, Science, Biotechnology, Women, FDA, Health, Other Science, Assistant, Education, University, UCLA, Population, Neurology, American Brain Tumor Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Anxiety, Multimedia, Patient, Nebraska Medicine, Clinical trial, Cannabinoid, Research, FDA, Cannabidiol, IND, PTSD, Infection, Reynolds, Student, UNMC, LDS, Safety, Psychiatry, Therapy, National, The Million-Year Centipede, or, Liquid Structures, Pharmaceutical industry, Dietary supplement, Medicine, EU

, the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at Nebraska Medicine.

Key Points: 
  • , the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at Nebraska Medicine.
  • The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDAs proprietary delivery technology.
  • An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA).
  • Dr. Rizzo also is the director of the National Institutes of Healths Great Plains IDeA Clinical and Translational Research Network.

CareCloud’s talkEHR Selected by University of Nebraska Medical Center

Retrieved on: 
Thursday, May 5, 2022
Practice management, University of Nebraska Medical Center, EHR, CareCloud, University, Record, Health, UNMC, Â, GLOBE, Nebraska Medicine, SVP, Organization, RCM, PXM, Solution, MTBC, Technology, Health information management

SOMERSET, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- CareCloud , Inc. (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that its talkEHR solution has been selected by the University of Nebraska Medical Center (UNMC) University Dental Associates, for its flexibility and scalability.

Key Points: 
  • SOMERSET, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- CareCloud , Inc. (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that its talkEHR solution has been selected by the University of Nebraska Medical Center (UNMC) University Dental Associates, for its flexibility and scalability.
  • CareCloud's Revenue Cycle Services and talkEHR are designed to help UNMC minimize downtimes and increase revenue.
  • Powered by talkEHR, UNMCs analytics will be available in real-time, giving the University the ability to move from scanned billing to a fully digital system.
  • To learn more about talkEHR, CareClouds integrated EHR and practice management solution for nimble practices and organizations, visit www.talkehr.com .

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

Retrieved on: 
Tuesday, April 12, 2022
Manuscript, Cancer, Clinical trial, Pancreatic cancer, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Food, LAPC, Inspectorate, Private Securities Litigation Reform Act, GLOBE, Program, Patient, University of Nebraska Medical Center, Lists of diseases, UNMC, Innovation, Company, Degenerative disease, Immune system, American, Erasmus MC, CRO, NYSE, Nebraska Medicine, FOLFIRINOX, Safety, AIM, FDA, PSLRA, Disease, University, Therapy, Survival, Pharmaceutical industry, Rintatolimod

OCALA, Fla., April 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today provided an update on its development program evaluating Ampligen® for the treatment of pancreatic cancer.

Key Points: 
  • Additionally, Ampligen has shown success in increasing survival rates and efficacy in the treatment of animal tumors when used in combination with checkpoint blockade therapies.
  • Ampligen is also being used as a monotherapy to treat pancreatic cancer patients in a named patient program approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.
  • We continue to be encouraged by the progress and data demonstrated by Ampligen for the treatment of pancreatic cancer.
  • Additionally, we continue to amass an encouraging growing body of data that supports our belief in Ampligen to offer an important treatment option to patients living with pancreatic cancer.